Skip to main content
  • Sign in
  • Help
BOPA
  • Why join BOPA
  • Pricing
  • Education
    • BOPA Introduction to Cancer Course 2025
    • Courses and eLearning
    • SACT Verification Hub (Passport)
    • Resource Library
    • Cancer Hub
    • Education & Training Standards
    • Let’s Talk About SACT – a BOPA Podcast
  • About BOPA
    • About BOPA
    • Welcome to BOPA
    • Executive Committee
    • Subcommittees & working groups
    • Affiliated Groups
    • Specialist Advisory Groups
    • International Groups
    • BOPA Fellows
    • Corporate Membership
    • BOPA membership FAQs
  • Conference
    • Latest Conference 2025
    • Abstract Submission Opens 31st March
    • Past Symposiums / Conferences
  • News & Events
    • News
    • Events calendar
    • Submit event
  • Menu iconLCC
    • LCC
    • Cancer Hub
  • Join BOPA
Join BOPA
BOPA Join BOPA
  • Why join BOPA
  • Pricing
  • Education
    • BOPA Introduction to Cancer Course 2025
    • Courses and eLearning
    • SACT Verification Hub (Passport)
    • Resource Library
    • Cancer Hub
    • Education & Training Standards
    • Let’s Talk About SACT – a BOPA Podcast
  • About BOPA
    • About BOPA
    • Welcome to BOPA
    • Executive Committee
    • Subcommittees & working groups
    • Affiliated Groups
    • Specialist Advisory Groups
    • International Groups
    • BOPA Fellows
    • Corporate Membership
    • BOPA membership FAQs
  • Conference
    • Latest Conference 2025
    • Abstract Submission Opens 31st March
    • Past Symposiums / Conferences
  • News & Events
    • News
    • Events calendar
    • Submit event
  • Menu iconLCC
    • LCC
    • Cancer Hub
  • Join BOPA

Home » Hypersensitivity Reactions

Hypersensitivity Reactions

BOPA encourages its members to share helpful documents that can benefit other members.  BOPA respects the intellectual property of original authors and requires anyone who uses other members’ work to include an acknowledgment of, or reference to, the source in their version.

DISCLAIMER:
BOPA is not the author or owner of some of the documents published on our website.  BOPA as a professional interest group will share documents via its website that are of interest to BOPA members, but has no responsibility for use of the documents and for any recommendations within the documents so members must use these at their discretion. BOPA cannot accept responsibility for any errors or omissions or for any consequences from application of information in the documents attached and make no warranty, expressed or implicit with respect to the contents of this webpage. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site or document(s) downloaded from it.

Posters and abstracts on the BOPA website remain the property of the authors and anyone wishing to reference or share this work must contact the authors directly. Abstracts subsequently published in JOPP follow copyright rules from JOPP.

Last reviewed: 22/03/23 by BOPA

Position Statement: BOPA supports the withdrawal of histamine 2 (H2) antagonists from paclitaxel pre-medication regimens following publication of research which demonstrates their lack of effect. January 2023

Positions Statements

View resources
Last reviewed: 22/03/23 by BOPA Committee

Histamine-2 (H2) antagonists can be safely removed from standard paclitaxel premedication regimens

Publications

View resources
Last reviewed: 22/03/23 by Sana Mahmood

Multi centre retrospective evaluation of Paclitaxel hypersensitivity reactions in the absence of H2 antagonist pre-medication

Abstracts

View resources
Last reviewed: 22/03/23 by Emma Foreman

A National Service Evaluation of Paclitaxel Pre medication Regimes for the Prevention of Hypersensitivity during a period of Ranitidine Shortage

Abstracts

View resources
Last reviewed: 22/03/23 by Emma Foreman

A Service Evaluation of Paclitaxel Hypersensitivity Reactions with and without Ranitidine Pre-medication at The Royal Marsden (RMH)

Abstracts

View resources
Last reviewed: 22/03/23 by BOPA

Guidance on the use of H2 antagonists for the prevention and management of hypersensitivity

Guidelines, Publications

View resources

Filter for resources

  • Types

  • Tags

  • Reset
BOPA logo
  • Why join BOPA
  • Pricing/Join
  • Conference 2024
  • Education
  • About
  • News & Events
  • Help
  • Go to LinkedIn
  • Go to Twitter
  • Go to Facebook
  • Go to Instagram
  • Go to Bluesky

© Copyright 2025 British Oncology Pharmacy Association.
Registered Charity No. 1065026

  • Privacy Policy
  • T&Cs Website
  • T&Cs Membership
  • Cookies
  • Contact
Designed and developed by Rouge
Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience when you browse our website and also allows us to improve our site. By continuing to browse the site, you are agreeing to our use of cookies.